Literature DB >> 15461892

International Travel: Recommendations for the HIV-infected Patient.

Lisa A Spacek, Thomas C Quinn.   

Abstract

In order to prevent travel-related diseases in patients infected with HIV, pretravel planning that includes vaccination, chemoprophylaxis, and behavioral modification is recommended. Many HIV-infected individuals successfully treated with highly active antiretroviral therapy may travel safely. However, patients with reduced CD4 lymphocyte counts are at increased risk for bacterial, mycobacterial, viral, fungal, and parasitic infections. Recommendations for vaccination and chemoprophylaxis are based on immune status and risk of infection. The efficacy of vaccination is dependant on CD4 lymphocyte count; inactivated and polysaccharide vaccines are considered safe in this population. Behavioral modifications to prevent food- and waterborne disease are an important component of disease prevention. A travel-health practitioner should review travel duration, destination, and activities, and assess the risk-benefit ratio of vaccination and chemoprophylaxis, in order to reduce the likelihood of travel-associated illness.

Entities:  

Year:  2004        PMID: 15461892     DOI: 10.1007/s11908-004-0040-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  16 in total

1.  Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.

Authors:  F P Kroon; J T van Dissel; J C de Jong; K Zwinderman; R van Furth
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

2.  Travel advice for HIV-infected individuals.

Authors:  Robin McKenzie
Journal:  Hopkins HIV Rep       Date:  2004-05

3.  Yellow fever vaccine is safe and effective in HIV-infected patients.

Authors:  Pierre Tattevin; Agnès Geremy Depatureaux; Jean Marc Chapplain; Mathieu Dupont; Faouzi Souala; Cédric Arvieux; Jean Dominique Poveda; Christian Michelet
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

Review 4.  Disseminated bacille Calmette-Guérin disease after vaccination: case report and review.

Authors:  E A Talbot; M D Perkins; S F Silva; R Frothingham
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

Review 5.  Vaccination and HIV: a review of the literature.

Authors:  M C Rousseau; J Moreau; J Delmont
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

6.  Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial.

Authors:  S A Tasker; J J Treanor; W B Paxton; M R Wallace
Journal:  Ann Intern Med       Date:  1999-09-21       Impact factor: 25.391

7.  Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response.

Authors:  J D Fuller; D E Craven; K A Steger; N Cox; T C Heeren; D Chernoff
Journal:  Clin Infect Dis       Date:  1999-03       Impact factor: 9.079

8.  Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.

Authors:  Y Khaliq; K Gallicano; C Tisdale; G Carignan; C Cooper; A McCarthy
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 9.  Travellers' diarrhoea.

Authors:  Charles D Ericsson
Journal:  Int J Antimicrob Agents       Date:  2003-02       Impact factor: 5.283

10.  Hepatitis A and B vaccination practices for ambulatory patients infected with HIV.

Authors:  Ellen M Tedaldi; Rose K Baker; Anne C Moorman; Kathleen C Wood; Jack Fuhrer; Robert E McCabe; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2004-04-28       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.